Treatment of hepatitis C virus infection in real life

JAMA Internal Medicine

Volumn 176, Issue 1, 2016, Pages 73-74

  Yee, Hal F ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL THERAPY; BACTERIAL PERITONITIS; COMPARATIVE STUDY; DRUG SAFETY; FATTY LIVER; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH DISPARITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY TEST; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SURGICAL MORTALITY; HEPATITIS C, CHRONIC; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84954567771     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.6659     Document Type: Note

References (8)

1. Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population [published online November 23, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed.2015.6011.
2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-954.
3. American Heart Association. Methodology manual and policies from the ACCF/AHA Task Force on Practice Guidelines. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm-319826.pdf. June 2010. Accessed October 14, 2015.
4. IMS Institute for Healthcare Informatics. Medicine use and spending shifts: a review of the use of medicines in the US in 2014. http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=3f140a4331e8c410VgnVCM1000000e2e2ca2RCRD. April 7, 2015. Accessed October 14, 2015.
5. Guy J, Yee HF Jr. Health disparities in liver disease: time to take notice and take action. Hepatology. 2009;50(1):309-313.
6. Chen AH, Murphy EJ, Yee HF Jr. eReferral: a new model for integrated care. N Engl J Med. 2013;368 (26):2450-2453.
7. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56(1):213-219.
8. Simon TG, Chung RT. The new hepatitis C virus bottleneck: can delaying therapy be justified? Hepatology. 2015;62(3):666-667.